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Background—Despite the fact that the inflammatory bowel diseases (IBD) and their treatments 
may affect physical appearance, the effect of IBD on body image is poorly understood. The aims 
of this study were to determine whether body image dissatisfaction (BID) changes over time in 
patients with IBD and to examine the demographic and disease-related variables associated with 
decreased body image.
Methods—Adults aged 18 and above in the Ocean State Crohn's and Colitis Area Registry with 
at least 2 years of follow-up were eligible for this study. All patients were enrolled within 6 
months of IBD diagnosis and followed prospectively. BID was assessed using a modified version 
of the Adapted Satisfaction With Appearance (ASWAP) questionnaire. Total ASWAP scores and 
2 sub-scores were calculated. To assess for changes over time, general linear models for correlated 
data were used for continuous outcomes and generalized estimating equations were used for 
discrete outcomes.
Results—Two hundred seventy-four patients were studied. BID was found to be stable over time 
among men and women with IBD despite overall improvements in disease activity. No differences 
were found in BID according to IBD subtype. Female gender, greater disease activity, higher 
symptom burden, longer duration of steroid use, dermatologic and musculoskeletal manifestations 
of IBD, and ileocolonic disease location among patients with Crohn's disease were associated with 
greater BID. Greater BID was associated with lower health-related quality of life (HRQOL).
Conclusions—BID remains stable in an incident cohort of IBD despite improved disease 
activity and is associated with lower HRQOL
Introduction
Body image encompasses body-related self-perceptions and self-attitudes, such as body 
(dis-)satisfaction.1 The subjective evaluation of one's appearance is a central aspect of body 
image.2 Negative body image is associated with depressive symptoms, social anxiety and 
avoidance of social situations, low self-esteem, disordered eating, and other forms of poor 
self-care.3,4 In addition, in adults it has been linked to decreased sexual satisfaction and 
impairments in interpersonal relationships.1,5
Body image dissatisfaction (BID) has been evaluated in adults with medical disorders in 
which appearance-related changes and disfigurements are readily visible and interpersonally 
salient. In such populations it has been shown that appearance-related changes can pose 
significant challenges to the preservation of positive self-esteem and body image.6 Among 
patients with inflammatory bowel diseases (IBD), BID has been poorly evaluated. A single-
center study by Muller et al. suggested that as many as two-thirds of patients with IBD have 
impaired body image, however, studies validating these findings using standardized 
measures are lacking.7
Although IBD is a disorder of the gastrointestinal tract, it is well known that both ulcerative 
colitis (UC) and Crohn's disease (CD) as well as their treatments can dramatically change 
the functioning and appearance of the body, which in turn may alter patients' body image 
and psychosocial well-being. Patients with active disease may experience changes in 
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appearance due to weight loss, hair loss, or one of several cutaneous manifestations of 
IBD.8,9 In addition, patients with CD may develop disfiguring fistulas to the skin and 
perineum. Even patient with disease in remission may experience changes in physical 
appearance due to the potential of corticosteroids to cause weight gain, lipodystrophy and 
acne, azathioprine and 6-mercaptopurine (6-MP) to cause photosensitivity, methotrexate to 
cause hair loss, and the tumor necrosis factor alpha (TNF)-α inhibitors to cause 
psoriasis.10-13 Furthermore, patients who undergo surgical management may struggle with 
the body-altering effects of scars and stomas.
The primary purpose of this study was to determine the prevalence of BID and its risk 
factors in adults with newly diagnosed IBD and the changes that occur in BID over time. A 
secondary goal was to examine the effect of BID on health-related quality of life (HRQOL) 
in patients with IBD.
Methods
Participants and Procedures
Patients aged 18 and above enrolled in the Ocean State Crohn's and Colitis Area Registry 
(OSCCAR) with a minimum of 2 years of follow-up were eligible for this study. OSCCAR 
is a community-based incident cohort of IBD based in the state of Rhode Island that was 
established in 2008. Subjects enrolled in OSCCAR have UC, CD, or inflammatory bowel 
disease undetermined (IBDU) based on endoscopy, radiology, and/or pathology. Eligible 
subjects must be enrolled within 6 months of diagnosis, with a median time to enrollment 
for adults of approximately 90 days from the date of diagnosis.
Subjects in OSCCAR undergo assessment of symptoms using a comprehensive symptom 
inventory, disease activity as measured by the Harvey-Bradshaw Index (HBI)14 for subjects 
with CD (range 0 to ∞) or Simple Clinical Colitis Index (SCCAI)15 (range 0 to 19) for 
subjects with UC or IBDU, medication use, surgical history, general and disease-specific 
HRQOL as measured by Inflammatory Bowel Disease Questionnaire (IBDQ)16 (range 32 to 
224, with higher scores indicating better quality of life) at the time enrollment and then 
every 6 to 12 months, depending on the outcome being measured. Disease location is 
recorded according to the Montreal Classification.17
To assess BID a modified version of the Adapted Satisfaction with Appearance (ASWAP) 
scale was administered.18 The ASWAP is an adaption of the Satisfaction With Appearance 
(SWAP) scale. SWAP and ASWAP measure non-weight-related BID at multiple body sites 
(e.g. face, extremities, chest) and social discomfort related to appearance. SWAP was 
developed and tested on burn victims where it was found to have good internal consistency 
and moderate test-retest reliability.19 ASWAP was administered to participants with 
scleroderma to evaluate its psychometric integrity and its validity for use in a different 
medical population that experiences changes in appearance.18 The ASWAP re-introduces a 
fifteenth item that was excluded from the final version of the SWAP (“My appearance 
makes others feel uncomfortable”) and changed items that included the word “burn” to 
“illness”. Principal component analysis of the ASWAP revealed two factors, Subjective 
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Dissatisfaction and Perceived Social Impact, rather than the four found in burn victims. We 
replaced an item addressing = satisfaction with scalp with an item about the abdomen.
On the SWAP and ASWAP, subjects are asked to rate the degree to which each item 
accurately reflects their thoughts and feelings about their appearance. Ratings are made on a 
7-point scale ranging from 1 (strongly disagree) to 7 (strongly agree). We calculated total 
modified ASWAP scores by subtracting 1 from each item in order to anchor queries at 0 and 
then adding items in the subscales. According to the initial description of the measure, 
questions corresponding to items 4–11 in the SWAP were reverse scored such that higher 
scores reflect greater dissatisfaction or distress .19Two sub-scores (Perceived Social Impact 
and Subjective Dissatisfaction) were calculated for each subject at baseline and at each 
follow-up time point.
OSCCAR has been approved by the Institutional Review Boards at Lifespan/Rhode Island 
Hospital, Massachusetts General Hospital, Icahn School of Medicine at Mount Sinai, and the 
University of Wisconsin School of Medicine and Public Health.
Data Analysis
We described the demographic characteristics, IBD subtype (CD, UC or IBDU), disease 
characteristics, medication use, IBD activity as assessed by the HBI and the SCCAI, 
symptoms, surgical history, and HRQOL as measured by the IBDQ of the cohort at baseline 
and follow-up. To assess changes in BID according to these factors, a general linear model 
for correlated data was used.
We used logistic regression to calculate the propensity score of steroids usage. At each time 
point, the predictors for the model included age at enrollment, disease activity score, total 
number of symptoms, indicators for other medication usage at current time points and 
indicators for steroids usage at previous time points. At baseline, we used a weighted 
regression analysis, with weight being the inverse probability of using steroids, to assess the 
steroids effect. Weighting was done to account for dissimilar characteristics between 
patients who do and do not take steroids, and achieve a pseudo-sample where the outcome is 
not confounded by the variables in the propensity score.20 Due to inconsistences in patient 
recall with regards to steroid dosing, we used duration of steroid use as a surrogate measure 
of steroid exposure. To evaluate the effect of the duration of steroid exposure on ASWAP 
scores we used marginal structural models.21 The current analysis is valid under the 
assumption of data “missing at random”. 22
Results
Study Population—Of 389 eligible subjects, 274 (70.4%) participated in this study (145 
CD, 129 UC/IBDU). Respondents were 61.7% female. The mean age (SD) of the subjects at 
diagnosis was 40.6 (16.8) and mean (SD) body mass index (BMI) was 27.4 (7.3). With 
regards to baseline disease activity, mean (SD) HBI score for subjects with CD was 3.2 (3.5) 
and mean (SD) SCCAI score for subjects with UC and IBDU was 2.7 (2.6) across three 
years. Further demographic information and disease characteristics of the population at 
baseline are summarized in Tables 1 and 2.
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Body Image Dissatisfaction—The modified ASWAP scores for subjects stratified by 
sex and adjusted for age and marital status at baseline and follow-up are summarized in 
Table 3. After adjusting for age and marital status, we did not find significant improvement 
in BID either by total ASWAP score or by either sub-scores, from baseline to year 2 of 
follow-up (p=0.08). BID remained stable over time for both males and females.
When comparing total ASWAP scores and sub-scores between sexes we found all scores at 
each time point to be significantly different between males and females (p<0.0001). Total 
ASWAP scores were 6.78 (SE 1.58) higher among females compared to males while 
Perceived Social Impact scores were 2.12 (SE 0.81) higher and Subjective Dissatisfaction 
scores were 4.58 (SE 0.92) higher, indicating greater BID among females compared to 
males.
After adjusting for age, marital status, and gender we found no association between BID and 
IBD subtype. Symptom burden, however, was associated with all BID scores (i.e. total 
ASWAP score and both sub-domain scores) wherein subjects with a greater number of 
symptoms had higher BID scores (p<0.0001). As expected, given that the ASWAP scale is a 
measure of non-weight related BID, BMI was not significantly associated with BID by any 
measures after adjusting for multiple comparisons (Table 4).
Disease location: With regards to disease location, we found significant differences in 
ASWAP scores among patients with CD wherein patients with ileocolonic disease (L3) had 
the highest BID scores while subjects with colonic disease (L2) had the lowest scores (Table 
4). No difference was found between patients with isolated ileal disease (L1) and patients 
with either L2 or L3 disease. Within the UC cohort, we found no significant difference in 
ASWAP scores by disease location. Compared to subjects without perianal disease, total 
ASWAP scores were estimated to be 3.60 (SE 4.76) higher for subjects with CD with 
perianal involvement after adjusting for age, gender, and marital status. This difference, 
however, was not significant. This may be due to insufficient power as only 8 subjects with 
CD had documented perianal disease at last follow-up.
Extraintestinal manifestations: When comparing total ASWAP scores and ASWAP sub-
scores between subjects with an extraintestinal manifestation (EIM) of IBD and without, we 
found all scores at each time point to be significantly different between the two groups 
(p<0.0001 (Table 4) Total ASWAP scores were 4.15 (SE 1.10) higher in subjects with an 
EIM compared to subjects without after adjusting for age, gender, and marital status. 
Perceived social impact and subjective dissatisfaction scores were 1.76 (SE 0.59) and 3.15 
(SE 0.71) higher in subjects with an EIM compared with subjects without.
Regarding specific EIMs, we found that over time, presence of musculoskeletal (p=0.0001) 
and dermatologic manifestations (p=0.03) were significantly associated with total ASWAP 
scores and that presence of ocular manifestation was not after adjusting for multiple 
confounders.
Surgery: Only 6 patients had a history of an IBD-related surgery at baseline and only 17 
had undergone IBD-related surgery by the end of follow-up. Comparing total ASWAP 
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scores between subjects who had and who had not undergone surgery at baseline and by the 
end of follow-up did not reveal a significant difference.
Medication usage: We analyzed the effect of IBD medication use on BID and found steroid 
use (current or recent) was significantly associated with greater BID by all measures at 
baseline and all subsequent time points (p=0.02) (Table 4). When comparing the effect of 
steroid use on BID by gender, we found that the changes in BID scores with steroid 
exposure were significantly different between males and females, wherein the magnitude of 
change in total ASWAP scores was greater in females compared to males (p=0.04). The 
mean difference in total ASWAP scores was 4.43 (SE 2.12) over all years.
Using logistic regression and after controlling for propensity for baseline steroid use, we 
found that steroid exposure at baseline was not significantly associated with any BID 
measure. Duration of steroid exposure, however, was associated with significantly higher 
total ASWAP scores after adjusting for multiple comparisons (p=0.0006). The estimated 
effect of one additional year of steroid exposure on total ASWAP scores was 6.3 (1.8). 
Longer steroid exposure was also associated with higher Perceived Social Impact scores 
(p=0.002) and higher Subjective Dissatisfaction scores (p=0.003). Interestingly, however, 
after adding other medication usage in the propensity model for steroid use, duration of 
steroid exposure was no longer significantly associated with any BID measure.
The same analyses were repeated to evaluate both the baseline and cumulative impact of 
thiopurine and anti-TNF exposure on BID. We did not find any significant associations 
between BID and these classes of medications.
Disease Activity Scores: Both SCCAI and HBI scores were found to significantly decrease 
over time (p=0.003 and 0.007, respectively). Among patients with CD, after adjusting for 
age, marital status and gender, we found that all BID scores were significantly associated 
with disease activity as measured by HBI at baseline and follow-up wherein higher HBI 
scores were associated with higher total ASWAP scores (p<0.0001) and higher ASWAP 
sub-scores (p=0.0002 for Perceived Social Impact and p<0.0001 for Subject Dissatisfaction) 
(Table 4). Among patients with UC/IBDU, we found that all BID scores were significantly 
associated with disease activity as measured by SCCAI at baseline and follow-up, where 
higher SCCAI scores were associated with higher total ASWAP scores (p=0.006) and higher 
Perceived Social Impact (p<0.0001) but not with greater Subjective Dissatisfaction.
HRQOL: We found IBDQ scores to be significantly associated with all BID scores among 
males and females wherein a 1 unit increase in the Subjective Dissatisfaction score was 
associated with a 0.75 (0.18) decrease in IBDQ scores and a 1 unit increase in the Perceived 
Social Impact score was associated with a 1.39 (0.16) decrease in IBDQ (p<0.0001) (Table 
5). A one unit increase in the total ASWAP score was associated with a 0.62 (0.08) decrease 
in IBDQ (p<0.0001).
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The evaluation of BID in adult patients with IBD has been limited to date. Given the 
potential for IBD and its treatments to alter physical appearance and the association between 
negative body image and poor self-esteem, poor interpersonal confidence, sexual 
dysfunction, and mood disorders, studies examining the impact of IBD on body image are 
important. In this study we used a non-weight based instrument to measure BID in subjects 
with IBD. Changes in BID over time were assessed according to multiple factors including 
gender, disease location, disease activity, and medication exposure. We also examined the 
relationship between BID and HRQOL as measured by the IBDQ. This is the first study to 
our knowledge which evaluates BID among IBD patients over time.
Using a community-based, incident cohort we found that BID does not improve over time 
for either sex despite the fact that overall disease activity improves. Furthermore, BID 
remains significantly greater among females with IBD compared to males at all time points. 
This gender difference is likely related to the greater importance that women attach to the 
appearance of their bodies compared to men and the greater satisfaction that men report with 
their bodies compared to women in the general population.23, 24 Although work by Feingold 
has found differences in body satisfaction between the sexes in adulthood to be less 
pronounced than in adolescence23, our results suggest that gender differences in BID are 
significant among adult patients with IBD and that women with either disease subtype are at 
particular risk for the detrimental consequences of negative body image.
Our longitudinal data analysis revealed several additional interesting findings. First, after 
controlling for multiple potential confounders, we found no significant difference in total 
ASWAP scores or ASWAP sub-scores according to IBD subtype. Thus, patients with UC 
and CD appear to be equally susceptible to BID. With regards to disease location, although 
we saw no difference in BID scores in patients with UC according to disease location, a 
significant difference was found between patients with ileocolonic CD and colonic CD, 
wherein patients with ileocolonic disease had greater BID than patients with isolated colonic 
disease. We postulate that differences in steroid usage between these groups may account 
for the difference in BID as we found steroid use at baseline to be significantly higher in 
patients with ileocolonic CD compared to patients with colonic involvement only (data not 
shown). In comparison, we found no differences in baseline steroid use among patients with 
UC according to disease location which may account for the stability in BID scores in this 
group.
We found no difference in BID among patients with CD according to perianal disease status. 
While small numbers of affected patients may have played a role in this finding, absence of 
a significant relationship between perianal disease and BID may be related to the relatively 
low importance that patients with CD have been found to place on the cosmetic appearance 
of perianal disease compared to its physical consequences.25 That is, patients may be more 
affected by the physical symptoms of perianal disease than its image-altering effects. In 
addition, we found that operative status was not associated with BID. Again, although this 
study may have been underpowered to find a significant association between these factors, it 
is important to note that several prior studies have also shown that body image scores do not 
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differ significantly in patients with IBD who have undergone laparoscopic-assisted versus 
open surgeries despite cosmesis scores being better in the laparoscopic group, suggesting 
that post-operative scarring may not be a major source of BID in patients with IBD.26, 27 
Only 1 patient in our cohort had undergone stoma surgery by the end of the years, thus we 
cannot make any conclusion about the effect of stomas on BID. Prior studies have shown 
that presence of a stoma diminishes body image satisfaction and sexual attractiveness in 
patients with IBD7,28, Longer follow-up of our cohort allowing for a greater number of 
surgeries is needed to further evaluate the impact of surgical therapy for IBD, particularly 
stoma surgery, on BID.
We found that BID was affected by symptom burden, disease activity, and certain EIM of 
IBD. With regards to symptom burden and disease activity, patients with higher symptom 
inventory scores and higher disease activity scores had greater BID. Thus, along with 
depression and anxiety which have been found to track with IBD activity 29, BID may be an 
additional psychological comorbidity for which patients with active disease are at risk and 
for which they should be assessed. Interestingly, while HBI scores were significantly 
associated with all 3 measures of BID in patients with CD, we did not find an association 
between Subjective Dissatisfaction scores and SCCAI scores in patients with UC. This may 
be due to differences in the degree and the nature of the physical appearance changes which 
occur in patients with active CD versus active UC. That is, patients with CD may experience 
more physical changes during periods of disease activity, perhaps related to malabsorption 
and weight loss, as compared to patients with UC, leading to greater subjective 
dissatisfaction with their appearance.
Regarding EIMs, we found that dermatologic and musculoskeletal manifestations of IBD 
were associated with greater BID. Given that the two most common IBD-associated 
dermatoses, erythema nodosum (EN) and pyoderma gangrenosum (PG), present in areas 
which can be kept “hidden” if so desired by clothing, it is notable that not only were 
Subjective Dissatisfaction scores greater in patients with these conditions so were Perceived 
Social Impact scores. This suggests that patients with IBD-related dermatoses perceive 
increased stigmatization due to their physical appearance even when they have the ability to 
keep their skin lesions out of public sight. Prior researchers have noted that mild 
disfigurements can cause equal or even greater anxiety than highly visible conditions.30 This 
may be due to the development of less consistent and effective coping mechanisms in 
patients with less noticeable physical changes such as patients with EN or PG whose lesions 
can be covered.31
Why the musculoskeletal manifestations of IBD are associated with greater BID is less clear 
given that most do not produce significant physical disfigurement. Differences in systemic 
steroid use for symptom management may provide some explanation and explain why 
patients with ocular manifestations who are typically treated with local therapy do not 
experience increased BID. Our medication analysis revealed that of the major classes of 
medications used to treat IBD only steroid use was significantly associated with BID. 
Univariate analysis found steroid use to be associated with all measures of BID. However, 
after controlling for multiple potential confounders including propensity for steroid usage, 
we found steroid use was significantly associated with higher Perceived Social Impact 
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scores only. We, therefore, propose that the dissatisfaction in body image experienced by 
IBD patients treated with steroids is more related to how they perceive others view them 
rather than to how they view themselves.
In addition, we found that the greater the duration of steroid exposure, the greater the BID 
that patients experience. Interestingly, this relationship was found to be modified by the 
concurrent use of steroid-sparing agents as when other medication use was added to our 
model, duration of steroid exposure was no longer significantly associated with BID. 
Steroid-sparing medications such as thiopurines and anti-TNF agents, therefore, appear to 
have the beneficial effect of reducing steroid-associated BID, possibly by lowering the dose 
of corticosteroid needed to manage symptoms. They also, notably, were not found to be 
independently associated with greater BID despite the potential side effects which can 
change physical appearance which are associated with both classes of medication.
Finally, we found greater BID to be significantly associated with lower IBDQ scores 
suggesting that body image plays a role in HRQOL in patient with IBD Interventions aimed 
at improving body image satisfaction, therefore, may be an appropriate target for improving 
HRQOL in this patient population.
This study provides important insight on BID in patients with newly diagnosed IBD. It is 
limited, however, by several factors. First, the ASWAP tool, although validated to measure 
BID in a population with a chronic medical illness, has not been validated in patients with 
IBD. It, therefore, may not have been the optimal measure for BID in this cohort. We do, 
however, consider it to be a reasonable exploratory tool as unlike the majority of measures 
of body image it is constructed to measure non-weight related BID. Furthermore, others 
groups have used modified versions of the SWAP to evaluate patient populations who are 
subject to lifelong changes in appearance due to their disease and have reported meaningful 
results. 32-up studies using this tool or the recently published body image scale are needed to 
confirm our findings and compare the magnitude of our findings to other IBD 
populations. 28 Second, few patients in our cohort had perianal disease or had undergone 
surgery by the end of follow-up. This study was therefore underpowered to determine 
whether these are risk factors for increased BID. Further follow-up of our cohort is needed 
to ascertain this. Finally, as our study did not include a healthy control group we are unable 
to determine the magnitude of body image impairment associated with a diagnosis of IBD in 
comparison to a healthy population.
Conclusions
In summary, using a community-based incident cohort we found that BID in patients with 
IBD remains stable over time despite improvements in disease activity. At all time points 
BID remains greater for females compared to males and is associated with lower HRQOL. 
Symptom burden, disease activity, dermatologic and musculoskeletal manifestations of IBD, 
and ileocolonic disease location for patients with CD were associated with greater BID 
while IBD subtype, ocular manifestations, and disease location among patients with UC 
were not. Longer follow-up of the cohort, allowing for a greater number of cases of perianal 
disease and IBD surgeries is needed to understand the relationship between these aspects of 
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the disease and body image. Of the major medication classes used to treat IBD only steroid 
use was associated with BID. Importantly, use of steroid-sparing medications was found to 
modify the detrimental effects of prolonged steroid use on body image satisfaction. 
Providers caring for patients with IBD should be aware of the risk factors for BID in this 
patient population given its impact on HRQOL as well as the potential for thiopurines and 
anti-TNFs to reduce the BID associated with steroid use.
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Appendix. Modified Adapted Satisfaction With Appearance Scale*
Using the following scale, please state your level of agreement with the statements below
1 2 3 4 5 6 7
Strongly disagree Disagree Somewhat disagree Neutral Somewhat agree Agree Strongly agree
1. Because of changes in my appearance caused by my illness, I am uncomfortable in the presence of my family.
2. Because of changes in my appearance caused by my illness, I am uncomfortable in the presence of my friends.
3. Because of changes in my appearance caused by my illness, I am uncomfortable in the presence of strangers
4. My appearance makes other people feel uncomfortable
5. Changes in my appearance have interfered with my relationships
6. I feel that my appearance is unattractive to others
7. I don't think people would want to touch me
8. I am satisfied with the appearance of my face.
9. I am satisfied with the appearance of my neck.
10. I am satisfied with the appearance of my hands
11. I am satisfied with the appearance of my arms
12. I am satisfied with the appearance of my legs.
13. I am satisfied with the appearance of my chest.
14. I am satisfied with the appearance of my abdomen
15. I am satisfied with my overall appearance.
*This survey has been adapted from Heinberg et al. [18].
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BMI <18.5 95 (34.7)
Classification 18.5-24.9 75 (27.4)
25-29.9 56 (20.4)
>30 48 (17.5)
Race Black or African American 11 (4.0)
White 248 (90.5)
More than one race 4 (1.5)
Other 10 (3.7)
Refused 1 (0.4)
Marital Status Married 102 (37.2)
Single/Never married 115 (42.0)
Divorced or Separated 34 (5.1)
Cohabitating 8 (2.92)
Widowed 1 (0.36)
Abbr: BMI=body mass index
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Table 2
Disease characteristics and patient history at baseline
Characteristic N (%)
Disease subtype CD 145 (53)
UC/IC 129 (47)
CD Location Ileal (L1) 29 (21.3)
Colonic (L2) 37 (27.2)
Ileocolonic (L3) 70 (51.5)
Upper disease (L4) 15 (10.8)
Data missing 9 (6.2)
CD Behavior Non-stricturing, non-penetrating (B1) 114 (82.0)
Stricturing (B2) 17 (12.2)
Penetrating (B3) 8 (5.8)
Perianal disease (p) 8 (5.8)
Data missing 6 (6.2)
UC Location Proctitis 22 (19.3)
Left-sided colitis 33 (29.0)
Pancolitis 59 (51.8)
Data missing 15 (11.6)
Extraintestinal Manifestations Dermatologic 32 (12.2)
Musculoskeletal 166 (63.1)
Ocular 50 (19.0)
History of IBD surgery Laparotomy 3 (1.01)
Bowel resection 2 (0.67)
Stoma 1 (0.34)
Perianal fistula repair 0 (0)





Anti-TNF agent 20 (7.3)
Mean (SD)
Disease activity score HBI (CD) 3.6 (3.6)
SCCAI (UC/IC) 3.1 (2.8)
IBDQ score Females 162.8 (32.8)
Males 174.8 (31.9)
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Abbr: CD=Crohn's disease, UC=ulcerative colitis, IC=indeterminate colitis, HBI=Harvey-Bradshaw Index, SCCAI=Simple Clinical Colitis 
Activity Index
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Table 3
Modified ASWAP scores




Baseline 30.1 (14.4) 21.2 (8.4)
Year 1 28.2 (14.1) 24.5 (12.5)
Year 2 28.8 (13.2) 24.1 (13.5)
Perceived Social Impact*
<0.0001
Baseline 11.5 (7.7) 8.3 (3.8)
Year 1 10.8 (7.8) 10.0 (6.7)
Year 2 10.5 (7.0) 10.2 (6.7)
Subjective Dissatisfaction Scale*
<0.0001
Baseline 18.5 (8.7) 12.9 (6.1)
Year 1 17.9 (8.2) 14.6 (6.9)
Year 2 18.3 (8.5) 13.9 (7.4)
p-value <0.0001 for gender, but insignificant for year.
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Table 4
Factors associated with BID
Outcome Variable Estimate Unadjusted p-value Adjusted p-value
Total modified ASWAP score
Year 0.75 0.15 1
Gender -6.78 <0.0001 <0.001
IBD subtype -0.69 0.64 1
Steroids use 2.24 0.03 0.3
Symptom Inventory Score 0.38 <0.0001 <0.001
BMI 0.26 0.008 0.08
HBI score 0.85 <0.0001 <0.001
SCCAI score 0.88 0.003 0.03
CD Location: L1 vs. L3 -3.33 0.26 1
CD Location: L2 vs. L3 -5.99 0.03 0.3
Perianal disease 2.79 0.56 1
UC Location: E1 vs. E3 1.28 0.66 1
UC Location:E2 vs. E3 -0.07 0.98 1
EIM 4.15 0.0002 0.002
Perceived Social Impact Scale score
Year 0.13 0.61 1
Gender -2.12 0.01 0.1
IBD subtype -1.02 0.18 1
Steroids use 1.54 0.004 0.04
Symptom Inventory Score 0.19 <0.0001 <0.001
BMI 0.09 0.06 0.6
HBI score 0.42 0.0006 0.006
SCCAI score 0.54 <0.0001 <0.001
CD Location: L1 vs. L3 -1.57 0.28 1
CD Location: L2 vs. L3 -3.66 0.009 0.09
Perianal disease 1.38 0.56 1
UC Location: E1 vs. E3 1.00 0.50 1
UC Location:E2 vs. E3 -0.42 0.75 1
EIM 1.96 0.002 0.02
Subjective Dissatisfaction Scale score
Year 0.58 0.08 0.8
Gender -4.58 <0.0001 <0.001
IBD subtype 0.39 0.66 1
Steroids use 0.81 0.21 1
Symptom Inventory Score 0.22 <0.0001 <0.001
BMI 0.16 0.007 0.07
HBI score 0.49 <0.0001 <0.001
SCCAI score 0.33 0.11 1
CD Location: L1 vs. L3 -1.74 0.30 1
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Outcome Variable Estimate Unadjusted p-value Adjusted p-value
CD Location: L2 vs. L3 -2.26 0.15 1
Perianal disease 2.11 0.43 1
UC Location: E1 vs. E3 0.73 0.69 1
UC Location:E2 vs. E3 0.25 0.87 1
EIM 2.92 <0.0001 <0.001
Abbr: BMI=body mass index, HBI=Harvey-Bradshaw Index, SCCAI=Simple Clinical Colitis Activity Index, CD=Crohn's disease, UC=ulcerative 
colitis, EIM=extraintestinal manifestation
*
Adjusted for age, gender, and marital status
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Table 5
Association between BID measures and HRQOL
Outcome Variable Estimate Unadjusted p-value Adjusted p-value
IBDQ
Perceived Social Impact -2.10 <0.0001 <0.001
Subjective Dissatisfaction Scale -1.52 <0.0001 <0.001
Total modified ASWAP score -1.17 <0.0001 <0.001
Abbr: IBDQ=Inflammatory Bowel Disease Questionnaire
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